Turtle Cameron

Chief Executive Officer, DirectorSpyre Therapeutics, Inc. (SYRE) · full profile →Form 4 · filed May 1, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$1.1M
Net Open-Market Flow
-$1.1M
Transactions
6
6 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 1, 2026Sell(S)5K$69.54$369K622K
May 1, 2026Sell(S)4K$70.77$255K619K
May 1, 2026Sell(S)1K$71.76$72K618K
May 1, 2026Sell(S)3K$73.14$227K615K
May 1, 2026Sell(S)2K$74.23$126K613K
May 1, 2026Sell(S)300$74.96$22K613K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001758363-26-000009) within minutes of acceptance. Every field above traces to the original document. Verify it directly: